Newsfeeds - Spark Newswire

3 minute read

US Stocks Open Lower; Dow Drops 1%

February 24, 10:44 AM

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to 11,413.98. The S&P 500 also fell, dropping, 1.22% to 3,963.44.

BAER

2 minute read

$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying

By Lisa Levin

January 25, 7:48 AM

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

APPN

1 minute read

Piper Sandler Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $21

By Benzinga Newsdesk

January 23, 7:30 AM

Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $18 to $21.

FULC

1 minute read

Reported Late Tuesday, Fulcrum Therapeutics Announces Pricing Of $125M Upsized Public Offering Of 9,615,384 Shares Of Common Stock At A Price Of $13/Share

By Benzinga Newsdesk

January 18, 1:44 AM

Fulcrum Therapeutics, Inc. ® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the pricing of

FULC

2 minute read

$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying

By Lisa Levin

January 9, 10:17 AM

Although US stocks closed sharply higher on Friday, there were a few notable insider trades.

COIN

1 minute read

Goldman Sachs Initiates Coverage On Fulcrum Therapeutics with Buy Rating, Announces Price Target of $11

By Benzinga Newsdesk

November 15, 5:48 AM

Goldman Sachs analyst Madhu Kumar initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Buy rating and announces Price Target of $11.

FULC

1 minute read

Credit Suisse Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $19

By Benzinga Newsdesk

November 9, 8:54 AM

Credit Suisse analyst Judah Frommer maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price target from $22 to $19.

FULC

1 minute read

Fulcrum Therapeutics Q3 EPS $(0.51) Beats $(0.62) Estimate, Sales $1.18M Miss $2.54M Estimate

By Benzinga Newsdesk

November 8, 8:19 AM

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.62) by 17.74 percent. This is a 10.53 percent increase over losses of $(0.57) per share

FULC

21 minute read

Earnings

Earnings Scheduled For November 8, 2022

By Benzinga Insights

November 8, 5:32 AM

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

ABCL

4 minute read

Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

October 20, 1:17 PM

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares jumped 126% to $0.4525 after the company announced its NextFintech division received commitment for a $15 million strategic investment.

ACOR